Positive CHMP opinion on first-in-class medicine to treat pulmonary arterial hypertension

EMA has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity.

Leave a Comment

Your email address will not be published. Required fields are marked *